Psoriasis assessment tools in clinical trials

被引:412
作者
Feldman, SR
Krueger, GG
机构
[1] Wake Forest Univ, Bowman Gray Sch Med, Dept Dermatol, Winston Salem, NC 27157 USA
[2] Univ Utah, Hlth Sci Ctr, Dept Dermatol, Salt Lake City, UT USA
关键词
D O I
10.1136/ard.2004.031237
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
In clinical practice, broad global assessments of psoriasis disease activity and its effect on patients' quality of life are used to assess the severity of patients' disease and their response to treatment. In clinical trials, more objective, validated instruments are required. Several such instruments have been developed and continue to be developed to provide an assessment of the severity of the skin lesions. Because a lesion's impact on patients' lives varies widely among patients, there has been growing recognition of the need to measure the quality of life impact of the disease along with the severity of the lesions.
引用
收藏
页码:65 / 68
页数:4
相关论文
共 24 条
[1]   CRITICAL-REVIEW OF THE INTERNATIONAL ASSESSMENTS OF HEALTH-RELATED QUALITY-OF-LIFE [J].
ANDERSON, RT ;
AARONSON, NK ;
WILKIN, D .
QUALITY OF LIFE RESEARCH, 1993, 2 (06) :369-395
[2]   Quality of life measures in psoriasis: a critical appraisal of their quality [J].
Ashcroft, DM ;
Po, ALW ;
Williams, HC ;
Griffiths, CEM .
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 1998, 23 (05) :391-398
[3]  
Ashcroft DM, 1999, BRIT J DERMATOL, V141, P185
[4]   TESTING THE VALIDITY OF THE EUROQOL AND COMPARING IT WITH THE SF-36 HEALTH SURVEY QUESTIONNAIRE [J].
BRAZIER, J ;
JONES, N ;
KIND, P .
QUALITY OF LIFE RESEARCH, 1993, 2 (03) :169-180
[5]   Efficacy of acitretin and commercial tanning bed therapy for psoriasis [J].
Carlin, CS ;
Callis, KP ;
Krueger, GG .
ARCHIVES OF DERMATOLOGY, 2003, 139 (04) :436-442
[6]   A 50% reduction in the Psoriasis Area and Severity Index (PASI 50) is a clinically significant endpoint in the assessment of psoriasis [J].
Carlin, CS ;
Feldman, SR ;
Krueger, JG ;
Menter, A ;
Krueger, GG .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2004, 50 (06) :859-866
[7]   Improved discriminative and evaluative capability of a refined version of Skindex, a quality-of-life instrument for patients with skin diseases [J].
Chren, MM ;
Lasek, RJ ;
Flocke, SA ;
Zyzanski, SJ .
ARCHIVES OF DERMATOLOGY, 1997, 133 (11) :1433-1440
[8]   Psoriasis clinical registries, genetics, and genomics [J].
Elder, JT .
ANNALS OF THE RHEUMATIC DISEASES, 2005, 64 :106-107
[9]   Effects of alefacept on health-related quality of life in patients with psoriasis - Results from a randomized, placebo-controlled phase II trial [J].
Ellis, CN ;
Mordin, MM ;
Adler, EY .
AMERICAN JOURNAL OF CLINICAL DERMATOLOGY, 2003, 4 (02) :131-139
[10]   The design of clinical trials in psoriasis: Lessons for clinical practice [J].
Feldman, SR .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2003, 49 (02) :S62-S65